Time for Change? Has the Time Come for the Pharmaceutical Industry to Accept Modest Prices?

In this article, Kate Dion teams up with industry leaders to write a thought-provoking piece for ISPOR's Value and Outcomes Spotlight focused on potential pricing strategies pharma could explore for COVID-19 medicines.

Click here to read the article.

This article was originally featured on ISPOR's Value and Outcomes Spotlight on December 14, 2020.

  • Share On

Recommended Posts

Taking the Proactive Path to Approval – The Strategic Advantage of Early Messaging in FDA Submissions

Book Review: The FDA Survival Manual – A Step-by-Step Guide to Preparing for a Successful ADCOM, 2nd Edition

Pink Sheet: Current, Former US FDA Adcomm Members' Reform Idea: Allow Conflicted Experts To Participate

New Survey of 400+ FDA Advisory Committee Members Weigh in on Recommendations for Reforms